IBRX
Immunitybio Inc
NASDAQ · Biotechnology
$6.05
+0.41 (+7.27%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 20.78M | 1.55B | 1.61B | 1.37B |
| Net Income | -584,182,873 | 174.18M | 206.87M | 144.80M |
| EPS | — | — | — | — |
| Profit Margin | -2,804.8% | 11.2% | 12.9% | 10.6% |
| Rev Growth | +151.2% | +14.4% | +15.1% | +21.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 19.54M | 1.85B | 1.81B | 2.26B |
| Total Equity | 2.96B | 2.71B | 2.28B | 2.30B |
| D/E Ratio | 0.01 | 0.68 | 0.80 | 0.98 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -446,386,239 | 310.76M | 319.11M | 261.81M |
| Free Cash Flow | — | 125.72M | 219.44M | 149.39M |